Erin Larkins

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> Mutations

Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal et al. · The Oncologist · 2018 · 212 citations · Full text

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Erin Larkins, Gideon M. Blumenthal, Weishi Yuan et al. · The Oncologist · 2017 · 210 citations · Full text

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions

Diana Bradford, Erin Larkins, Sirisha L. Mushti et al. · Clinical Cancer Research · 2020 · 161 citations

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib

Erin Larkins, Gideon M. Blumenthal, Huanyu Chen et al. · Clinical Cancer Research · 2016 · 119 citations

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions

Janice Kim, Diana Bradford, Erin Larkins et al. · Clinical Cancer Research · 2021 · 99 citations

Thyroid Cancers, Cancer Management, Radiation Oncology +16